Tyrosine-Protein Phosphatase Nonreceptor Type 12 Is a Novel Prognostic Biomarker for Esophageal Squamous Cell Carcinoma
Tyrosine-Protein Phosphatase Nonreceptor Type 12 Is a Novel Prognostic Biomarker for Esophageal Squamous Cell Carcinoma
复制标题
DOI：
10.1016/j.athoracsur.2011.12.056
复制
发表时间：
2012-05-01
影响因子：
4.6
通讯作者：
Wen, Zhe-Sheng
中科院分区：
文献类型：
--
作者：
Cao, Xun;Li, Yong;Wen, Zhe-Sheng
背景酪氨酸蛋白磷酸酶非受体12型（PTPN 12）被认为是一种肿瘤抑制因子。它在人类癌症中起着重要作用，但其在食管鳞状细胞癌（ESCC）中的临床病理和预后意义尚未阐明。我们使用Western blot检测了20对手术切除的食管组织中PTPN 12的表达。通过免疫组化检测260例手术切除的ESCC的组织芯片中的PTPN 12，其中260例来自原发癌部位，60例来自匹配的癌旁正常组织。统计分析PTPN 12的表达与临床病理因素及复发的关系。Western blot结果显示PTPN 12在正常食管癌旁组织中的表达水平高于食管鳞癌组织。免疫组化结果显示，PTPN 12在食管鳞癌中的高表达率为62.1%，低表达率为37.9%。多因素分析显示，PTPN 12蛋白表达水平与pN状态和肿瘤分级沿着，是独立的、有意义的预测因素（p < 0.001）。PTPN 12高表达的患者的无病生存期和总生存期较长（分别为p = 0.002和p = 0.001），尤其是II期患者（均为p < 0.001）。我们的研究表明PTPN 12蛋白表达是ESCC患者有价值的生物标志物。PTPN 12的高表达与ESCC患者良好的无病生存期和总生存期相关。(Ann Thorac Surg 2012;93：1674-81）（C）2012年，胸外科医师协会
Background. Tyrosine-protein phosphatase nonreceptor type 12 (PTPN12) is considered to be a tumor suppressor. It plays a significant role in human cancer, but its clinicopathologic and prognostic significance in esophageal squamous cell carcinoma (ESCC) has not yet been elucidated.Methods. Using Western blot, we evaluated the PTPN12 expression in 20 pairs of surgically resected esophageal tissues. The PTPN12 was detected by immunochemistry in a tissue microarray from 260 surgically resected ESCCs, of which 260 were from primary cancer sites and 60 were from matched paracancerous normal tissues. Statistical analyses were applied to test the associations between PTPN12 expression, clinicopathologic factors, and prognosis.Results. Western blots showed that the expression level of PTPN12 was higher in normal paracancerous esophageal tissues than in ESCC tissues. By immunohistochemical analysis, high and low expression of PTPN12 was found in 62.1% and 37.9% of ESCCs, respectively. After multivariate analysis, along with pN status and tumor grade, the protein expression level of PTPN12 was an independent and significant predictive factor (p < 0.001). Patients with PTPN12-high tumors had a longer disease-free survival and overall survival (p = 0.002 and p = 0.001, respectively), especially for those with stage II disease (both p < 0.001).Conclusions. Our study suggests that PTPN12 protein expression is a valuable biomarker for ESCC patients. High expression of PTPN12 is associated with favorable disease-free survival and overall survival in ESCC patients. (Ann Thorac Surg 2012;93:1674-81) (C) 2012 by The Society of Thoracic Surgeons